Dimitroulopoulos D, Xinopoulos D, Tsamakidis K, et al. The role of somatostatinLAR in treating patients with advanced hepatocellular cancer[J]. Hepatogastroenterology, 2002,49:1245-1250.
[2]
Yuen MF, Poon RT, Lai CL, et al. A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma[J]. Hepatology, 2002,36:687-691.
[3]
Tomassetti P, Migliori M, Corinaldesi R, Gullo L. Treatment of gastroenteropa-ncreatic neuroendocrine tumours with octreotide LAR[J]. Aliment Pharmacol Ther, 2000,14:557-560.
[4]
Reynaert H, Rombouts K, Vandermonde A, et al. Expression of somatostatin receptors in normal and cirrhotic human liver and in hepatocellular carcinoma[J]. Gut, 2004,53(8): 1180-1189.
[5]
Guillermet-Guibert J, LahlouH, CordelierP, et al. Physiology of somatostatin receptors[J]. Endocrinol Invest, 2005, 28(11): 5-9.
Yusuke Taniyama, Takashi Suzuki Yoshiki Mikami. Systemic dis-tribution of somatostatin receptor subtypes in human: An immuno-histochemical study[J]. Endocrine Journal, 2005,52(5):605-611.
[8]
Dimitroulopoulos D,Xinopoulos D,Tsamakidisk,et al.Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors:randomized placebo-controlled trial[J].World JGastroenterol,2007,13(23):3164-3170.
Kouroumalis E, Skordilis P, Thermos K, et al. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study[J]. Gut, 1998,42:442-447.
[12]
Gulec SA, Drouant GJ, Fuselier J, et al. Antitumor and antiangiogenic effectors of somatostatin receptor-targeted in situ radiation with <111> In DTPAJ IC 2DL[J]. J Surg Res, 2001,97:131-137.
[13]
Buchan AM, Lin CY, Choi J, et al. Somatostatin, acting at receptor subtype 1,inhibits rho activity, the assembly of actin stress fibers, and cell migration[J]. J Biol Chem, 2002, 277:28431？28438.
